Treace Medical Concepts, Inc. (TMCI) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	205.3M	212.7M	209.4M	187.1M	141.8M
Cost of Revenue	42.2M	42.9M	41.1M	35.2M	27.5M
Gross Profit	163.1M	169.8M	168.3M	151.9M	114.3M
Operating Expenses
R&D Expense	18.2M	20.3M	20.6M	15.4M	13.6M
SG&A Expense	197.6M	203.6M	203.4M	187.9M	137.6M
General & Admin Expense	62.2M	62.7M	55.7M	47.0M	33.0M
Selling & Marketing Expense	135.4M	140.9M	147.6M	140.9M	104.6M
Other Expenses	1.0M	—	—	—	(2.0M)
Total Operating Expenses	216.8M	223.9M	224.0M	203.4M	149.2M
Cost and Expenses	259.0M	266.8M	265.0M	238.5M	176.7M
Operating Income (EBIT)	(53.7M)	(54.2M)	(55.7M)	(51.4M)	(34.8M)
Non-Operating
Interest Income	2.1M	2.8M	4.9M	6.7M	1.3M
Interest Expense	5.8M	5.3M	5.3M	5.2M	4.4M
Net Interest Income	(3.7M)	(2.5M)	(379.0K)	1.6M	(3.1M)
Other Non-Op Income/Expense	(5.8M)	(4.8M)	(55.0K)	1.9M	(8.0M)
Non-Operating Income (excl Interest)	(27.0K)	(472.0K)	(5.2M)	(7.1M)	3.6M
EBT (Pre-Tax Income)	(59.5M)	(59.0M)	(55.7M)	(49.5M)	(42.8M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(59.5M)	(59.0M)	(55.7M)	(49.5M)	(42.8M)
Earnings from Cont. Ops	(59.5M)	(59.0M)	(55.7M)	(49.5M)	(42.8M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(59.5M)	(59.0M)	(55.7M)	(49.5M)	(42.8M)
Per Share
Basic EPS	($0.93)	($0.93)	($0.90)	($0.81)	($0.77)
Diluted EPS	($0.93)	($0.93)	($0.90)	($0.81)	($0.77)
Revenue Per Share	$3.16	$3.36	$3.37	$3.07	$2.57
Shares
Basic Shares Outstanding	65.0M	63.3M	62.1M	60.9M	55.3M
Diluted Shares Outstanding	65.0M	63.3M	62.1M	60.9M	55.3M
Profitability Metrics
EBITDA	(45.3M)	(43.2M)	(42.1M)	(39.0M)	(36.3M)
D&A	8.4M	10.5M	8.4M	5.4M	2.1M
EBIT	(53.7M)	(53.7M)	(50.5M)	(44.4M)	(38.4M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026